AI Insight
A study examining patients taking GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and liraglutide (Saxenda) found that individuals who achieved significant weight loss experienced substantially reduced risks of obesity-related conditions, including sleep apnea and chronic kidney disease. Conversely, patients who gained weight during treatment showed elevated health risks, particularly for heart failure. These outcomes were observed despite a high rate of medication discontinuation within the first year of treatment.
Why it matters
These findings reinforce the clinical importance of sustained weight loss through GLP-1 therapies and highlight that treatment adherence and weight trajectory, rather than medication use alone, are key determinants of health outcomes. This has direct implications for how clinicians monitor and support patients on these medications over time.
People who lost significant weight while taking Ozempic, Wegovy, Mounjaro, or Saxenda had sharply lower risks of major obesity-related health problems, including sleep apnea and kidney disease. Those who gained weight instead faced higher risks — especially for heart failure — even though many patients discontinued the medications within a year.
Source: People who lost the most weight on Ozempic saw huge health benefits